CRVS
$15.45
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Intraday
Recent News
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains
Corvus Pharmaceuticals (CRVS) has recently drawn attention after a 91.3% gain over the past 3 months, alongside a 255.8% 1 year total return. This has prompted investors to reassess its risk and potential. See our latest analysis for Corvus Pharmaceuticals. Those moves sit alongside a 118.7% year to date share price return and a very large 3 year total shareholder return. The recent 30 day share price decline of 18.2% suggests some of that momentum has cooled near the current US$16.01...
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Corvus Pharmaceuticals, Inc.'s Q4 2025 earnings call
Corvus (CRVS) Q4 2025 Earnings Call Transcript
For both the fourth quarter and full year 2025, the increases in R&D expenses were primarily due to higher clinical trial and manufacturing costs associated with the development of soquelitinib as well as an increase in personnel costs. Included in the net loss for the fourth quarter of 2025 and 2024 were noncash losses of $0.7 million and $2.2 million, respectively, from Corvus' equity method investment in Angel Pharmaceuticals and a noncash loss of $2.3 million in the fourth quarter of 2024 associated with the change in fair value of the company's warrant liability.
Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...
Corvus Pharmaceuticals Inc (CRVS) reports promising trial results and a robust financial position, despite increased research expenses and a slight rise in net loss.
Corvus Pharmaceuticals Q4 Earnings Call Highlights
Corvus Pharmaceuticals (NASDAQ:CRVS) outlined expanding clinical plans for its selective ITK inhibitor soquelitinib while reporting higher research and development spending for 2025, reflecting a broader and more advanced pipeline. Management emphasized recent atopic dermatitis data, ongoing enrollm